1[1]MTCG.Combination chemotherapy versus melphalan plus prednison as treatment for multiple myeloma:an oveview of 6 633 patients from 27 randomized trials.By the Myeloma Trialists Collaborative Group.J Clin Oncol,1998,16:3822-3842.
2[2]Barlogi B,Jagannath S,Naucke S et al.Long-term follow-up after high-dose therapy for high-risk multiple myeloma.Bone Marrow Transplant,1998,21:1101-1107.
3[3]Desikan R,Barlogie B,Sawyer J,et al.Results of highdose therapy for 1000 patietns with multiple myeloma:durable complete remissions and superior survival in the absence of chromosome 13 abnormalities.Blood,2000,95:4008-4010.
4[4]Fermand JP,Ravaud P,Chevret S,et al.High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma:up-from or rescue treatment?Results of multicenter sequential randomized clinical trial.Blood,1998,92:3131-3136.
5[5]Munshi NC,Barlogie B,Desikan KR,et al.Novel approaches in myeloma therapy.Semin Oncol,1992,26:28-34.
6[6]Badros A,Barlogie B,Morris C,et al.High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions Blood,2001,97:257-42579.
7[7]The Myeloma Trialists Collaborative Group,Interferon as therapy for multiple myeloma:an individual patient data overview of 24 randomized trials and 4012 patients.Br J Haematol,2001,113:1020-1034.
9[9]Mitsiades N,Mitsiades CS,Poulaki V,et al.Apoptotic signaling induced by immunomodulatory thalidomide analogs (Imids) in human multiple myeloma cells:therapeutic implications.Blood,2001,98:775-778.
10[10]Hideshima T,Chauhan D,Shima Y,et al.Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.Blood,2000,96:2943-2950.
5Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial [J]. Lancet, 2006, 367 (9513): 825- 831.
6Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma [ J ]. N Engl J Med, 2003, 348 (26): 2609-2617.
7Richardson PG, Sonneveld P,. Schuster MW, et al. Bortezomib or high - dose dexamethasone for relapsed multiple myeloma [J]. N Engl J Med, 2005, 352 (24): 2487 - 2498.
8Berenson JR, Hillner BE, Kyle RA, et al. American society of clinical oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma [ J ]. J Clin Oncol, 2002, 20 (17): 3719-3736.
9张之南,沈悌.血液病诊断及疗效标准[M].3版.北京:科学出版社,2008:232-235.
10Tcheng WY, Said J, Hall T, et al. Post - transplant multiple myeloma in a pediatric renal transplant patient [ J ]. Padiadr Blood Cancer, 2006, 47 (2): 218-223.
